Antoine Beret - Transgene Independent Director
| TRGNF Stock | USD 1.62 0.00 0.00% |
Director
Mr. Antoine Beret was NonExecutive Independent Director of Transgene since May 24, 2016. He is also Chief Executive Officer of Pharma SAS and Chairman of Axenis.30. He is cofounder of several biotechs as Trophos and Immunotech. since 2016.
| Age | 72 |
| Tenure | 8 years |
| Phone | 33 3 88 27 91 00 |
| Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Seth Herbst | Dyadic International | N/A | |
| Theodore Wang | TRACON Pharmaceuticals | 50 | |
| Martin Mattingly | TRACON Pharmaceuticals | 60 | |
| William LaRue | TRACON Pharmaceuticals | 66 | |
| Rainer Twiford | TRACON Pharmaceuticals | 64 | |
| Andre Klaassen | Dyadic International | N/A | |
| Jack Kaye | Dyadic International | 70 | |
| Raquel MS | HCW Biologics | N/A | |
| Robert Burke | Dyadic International | N/A | |
| Barry Buckland | Dyadic International | 67 | |
| Alfred Scheidegger | TRACON Pharmaceuticals | 58 | |
| Stephen Worland | TRACON Pharmaceuticals | 59 | |
| Michael Tarnok | Dyadic International | 59 | |
| Frank Gerardi | Dyadic International | 62 | |
| Stephen Warner | Dyadic International | 75 | |
| Arindam Bose | Dyadic International | N/A | |
| Ted Wang | TRACON Pharmaceuticals | 50 | |
| Paul Walker | TRACON Pharmaceuticals | 43 | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christophe Ancel, Vice President - Quality and Qualified Person, Member of the Management Committee | ||
| Philippe Archinard, Chairman and CEO | ||
| Maya Said, Non-Executive Independent Director | ||
| Hedi Brahim, CEO Director | ||
| PierrePatrick Hurteloup, Independent Director | ||
| Arnaud Fayet, Independent Director | ||
| Patrick Mahieux, VP of Industrial and Pharmaceutical Operations | ||
| John Felitti, General Counsel, Member of the Management Committee, Corporate Secretary | ||
| Eric Quemeneur, Executive Vice President Vice President - Research & Development, Member of the Management Committee | ||
| Gaelle Stadtler, VP HR | ||
| Hemanshu Shah, Vice President - Medical Affairs and International Development, Member of the Management Committee | ||
| Elisabeth Keppi, Deputy CEO, Qualified Pharmacist, Director of Quality Assurance and Compliance, Member of the Management Committee | ||
| Elisabetta Castelli, Director of Investor Relations | ||
| Steven RPh, VP Officer | ||
| Nathalie Adda, Chief Medical Officer and VP | ||
| JeanLuc Belingard, Director | ||
| MarieYvonne Landel, Non-Executive Independent Director | ||
| Thibaut Fayet, VP of Alliance Management, Project Management and Marketing | ||
| Dominique Takizawa, Director - Permanent Representative of TSGH | ||
| Ghislaine Gilleron, General Secretary and Secretary to the Management Committee, General Counsel, Member of the Management Committee | ||
| JeanPhilippe Del, Vice President - Finance, Member of the Management Committee | ||
| JeanYves Bonnefoy, Vice President Research and Development, Member of the Management Committee | ||
| JeanFrancois Labbe, Independent Director | ||
| Laurence Zitvogel, Director | ||
| Colin Freund, VP of Bus. Devel. | ||
| Alain Merieux, Director | ||
| LLM JD, Gen VP | ||
| Maud MD, VP Officer | ||
| Antoine Beret, Independent Director | ||
| Benoit Habert, Independent Director | ||
| Laurence Bertaud, Director of Human Resources, Member of the Management Committee | ||
| Lucie Larguier, Director IR | ||
| JeanPierre Bizzari, Independent Director | ||
| Maud Brandely, Member of the Management Committee, Vice President - Clinical Development, Clinical Operations and Regulatory Affairs | ||
| Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Transgene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Transgene's short interest history, or implied volatility extrapolated from Transgene options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Transgene SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Transgene Pink Sheet analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |